EP2897967A1 - Chelates, chelating agents, conjugates derived thereof and their use - Google Patents

Chelates, chelating agents, conjugates derived thereof and their use

Info

Publication number
EP2897967A1
EP2897967A1 EP13783074.1A EP13783074A EP2897967A1 EP 2897967 A1 EP2897967 A1 EP 2897967A1 EP 13783074 A EP13783074 A EP 13783074A EP 2897967 A1 EP2897967 A1 EP 2897967A1
Authority
EP
European Patent Office
Prior art keywords
group
coo
coor
biomolecule
chelate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP13783074.1A
Other languages
German (de)
French (fr)
Other versions
EP2897967B1 (en
Inventor
Qi Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2897967A1 publication Critical patent/EP2897967A1/en
Application granted granted Critical
Publication of EP2897967B1 publication Critical patent/EP2897967B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10—Non-macromolecular compounds
    • C09K2211/1003—Carbocyclic compounds
    • C09K2211/1007—Non-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10—Non-macromolecular compounds
    • C09K2211/1018—Heterocyclic compounds
    • C09K2211/1025—Heterocyclic compounds characterised by ligands
    • C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/18—Metal complexes
    • C09K2211/182—Metal complexes of the rare earth metals, i.e. Sc, Y or lanthanide

Definitions

  • This invention relates to stable luminescent lanthanide(III) chelates and biomolecules labeled with these chelates. This invention further relates to the use of the chelates in a method of carrying out a biospecific binding assay. The invention relates also to chelating agents useful in solid phase synthesis of oligopeptides and oligonucleotides and oligopeptide and oligonucleotide conjugates so obtained.
  • Luminescent lanthanide(III) chelates have several special properties that make them excellent tools in especially homogenous bioaffinity assays. Their large Stokes' shift has a decreasing effect on scattering phenomena. The long fluorescence decay after excitation of these molecules allow time-resolved signal detection, which eliminates completely the background luminescence originating, e.g. from buffer components, plastics, and biomaterials. The very narrow emission lines allow the use of effective filters which diminish the background. Furthermore, since the lanthanide(III) chelates do not suffer from concentration quenching it is possible to have several chelates in close proximity enabling multilabeling. This phenomenom allows also the development of chelates bearing several light absorbing moieties.
  • the optimal luminescent lanthanide chelate must be stable in the presence of additional chelators even at low pH and high temperature.
  • the chelate should have optimal emission profile, high hydrophilicity, small size, good biocompatibility, little effect on biomolecules and good energy transfer properties.
  • the chelate should be feasible for different energy acceptors, and when possible, the synthesis of the molecule should be simple, cheap and scalable.
  • Europium(III) chelate of 4-[2-(4-isothiocyanatophenyl)ethynyl]-2,6,-bis ⁇ [N,N- bis(carboxymethyl)-amino]methyl ⁇ pyridine [US 4,920,195] is one of the most commonly used biomolecule labeling reagent, since it fulfills almost all of the above mentioned requirement.
  • the most serious drawback of this chelate as well as other 7-dentate lanthanide(III) chelates is that it exhibits rather low chelate stability limiting its use in applications involving treatments at elevated temperature, low pH and in the presence of additional chelating agents such as EDTA.
  • the chelate stability can be increased by using cyclic chelating moieties [US 4,920,195; WO2005058877; WO2005021538] but neutralization of the net charge decreases the water solubility of the chelate.
  • the decreased solubility of the cyclic chelates can be enhanced by using hydrophilic groups at the aromatic unit [WO2009030819].
  • the chelate stability can be enhanced also by increasing the number of chelating carboxylic acids [WO2008020113, US2004166585].
  • all the prior art methods for increasing chelate stability of chelates including pyridine subunit also increase the size of the chelate and/or decrease the chelate solubility.
  • An object of the present technology is to alleviate and eliminate the problems related to the luminescent lanthanide chelates of prior art.
  • this technology concerns chelates including a lanthanide(III) ion selected from europium, terbium, samarium and dysprosium and a chelating ligand of formula
  • X is an aromatic unit
  • A is a reactive group selected from isothiocyanate, bromoacetamido, iodoacetamido, maleimido, 4,6-dichloro-l,3,5-triazin-2-ylamino, pyridyldithio, thioester, aminooxy, azide, hydrazide, amino, alkyne, a methacroyl group, carboxylic acid, acid halide, and an active ester, wherein A ' is cleaving group selected from CI, (CH 3 ) 2 SO, H 2 0, and N0 3 wherein - is the position of the linker L and
  • R a is selected from -CH 2 COO and -(CH 2 ) n N(CH 2 COO " ) 2 , wherein n is 2 or 3, and R b is-(CH 2 ) m N(CH 2 COO " ) 2 , wherein m is 2 or 3, and
  • R c is selected from CH 2 COO-, and -(CH 2 )iN(CH 2 COO ⁇ ) 2 , wherein 1 is 2 or 3. According to another aspect this technology concerns a chelating agent of formula II
  • A is a reactive group selected from the group consisting of carboxylic acid or its salt, acid halide, carboxylic acid ester, an amino acid residue -CH(NHR 1 )R 2 where R 1 is a transient protecting group and R 2 is a carboxylic acid or its salt, carboxylic acid halide or an active ester and a group of -Z 1 -0-PZ 2 -0-R 3 where one or two of the oxygen atoms optionally is replaced by sulfur, Z 2 is chloro or NR 4 R 5 , R 3 is a protecting group, R 4 and R 5 are alkyl groups including 1-8 carbons, Z 1 is absent or is a radical of a purine base or a pyrimidine base wherein the base is connected to the oxygen atom via either a) a hydrocarbon chain, which is substituted with a protected hydroxymethyl group, or b) a furan ring or pyrane ring, and R d is selected from -CH 2 COOR" and -(CH 2
  • R e is -(CH 2 ) m N(CH 2 COOR " ) 2 , whereinm is 2 or 3, and
  • R f is selected from CH 2 COOR", and -(CH 2 )1N(CH 2 C00R " ) 2 , wherein 1 is 2 or 3 and wherein R" is a protecting group.
  • this technology concerns a detectable molecule such as a biomolecule conjugated with a chelate according the present technology wherein the biomolecule is selected from the group consisting of oligopeptide, oligonucleotide, DNA, RNA, modified oligo- or polynucleotide, protein, oligosaccharide, polysaccharide, phospholipide, PNA, LNA, antibody, antigen, steroid, biotin, hapten, drug, receptor bindig ligand, and lectine.
  • this technology concerns a detectable molecule such as a biomolecule obtained by synthesis on a solid phase by introduction of a chelating agent according to the present technology into the biomolecule structure followed by deprotection and introduction of a lanthanide ion.
  • the present technology concerns a method of carrying out a specific bioaffinity assay using a biomolecule conjugate of the present technology with an analyte to be determined.
  • the present technology concerns a use of a biomolecule conjugate according to the present technology in a specific bioaffinity binding assay utilizing fluorometric or time -resolved fluorometric determination of a specific luminescence.
  • Figure 1 discloses the structures of the chelate of prior art (1) and two representative chelates according to the present technology (6,7).
  • Figure 4 discloses hCRP immunoassays with biotin-conjugated europium chelates: lc ( ⁇ ), 6c ( ⁇ ), and 7c (A).
  • the lower limit of detections for the biotin chelates were 6.5, 1.5 and 1.9 ⁇ g/L, respectively.
  • the present technology concerns chelates including a lanthanide(III) ion selected from europium, terbium, samarium and dysprosium and a chelating ligand of formula (I)
  • X is an aromatic unit
  • R a is selected from -CH 2 COO and -(CH 2 ) n N(CH 2 COO " ) 2 , wherein n is 2 or 3, and R b is-(CH 2 )mN(CH 2 COO " ) 2 , wherein m is 2 or 3, and
  • R c is selected from CH 2 COO-, and -(CH 2 ) 1 N(CH 2 COO " ) 2 , wherein m is 2 or 3.
  • R a is selected from -CH 2 COO " and
  • the chelates of the present technology have the following structures
  • L and A are as defined above, and Ln is selected from Eu, Tb, Sm, and Dy.
  • the parent compound is the part of the chelating ligand of formula (I) that is between the square brackets. Accordingly, the parent compound is understood as
  • the "aromatic unit” is a chemical compound that contains conjugated planar ring system with delocalized pi electron cloud instead of discrete alternating single and double bonds.
  • Exemplary aromatic units suitable for the present technology are phenylethynyl, furyl, thienyl, phenyl, and pyrrole groups, and their substituted derivatives.
  • Exemplary substituents are alkyl groups and alkoxy groups.
  • alkyl group is linear or branched, like methyl, ethyl, /? -propyl, /-propyl, /? -butyl, /-butyl and sec -butyl group.
  • the alkyl group can be tethered also to other groups like hydroxyl, carboxylic acid, carbohydrate and sulfonic acid groups.
  • alkoxy group can be linear or branched, like methoxy, ethoxy, n- propoxy, /-propoxy, n-butoxyl, /-butoxyl and sec-butoxy group.
  • the alkoxy group can be tethered also to other groups like hydroxyl, carbohydrate, carboxylic acid and sulfonic acid groups.
  • Exemplary alkoxy and alkyl substituted aromatic units are wherein - is the position of wherein the aromatic unit is connected to the pyridine unit and wherein -CH 2 COOH and -COOH groups are exemplary reactive groups A.
  • the aromatic unit is connected to 3- or preferably to 4-position of the pyridine unit.
  • the chelate must bear a reactive group A in order to enable covalent binding to a detectable molecule such as to a biomolecule.
  • the reactive group A is selected from the group consisting isothiocyanate, bromoacetamido, iodoacetamido, maleimido, 4,6-dichloro-l,3,5-triazin-2- ylamino, pyridyldithio, thioester, aminooxy, azide, hydrazide, amino, alkyne, a polymerizable group such as methacroyl group, and a carboxylic acid or carboxylic acid halide or an active ester thereof.
  • active ester is an aryl ester, vinyl ester, or hydroxyamine ester.
  • Exemplary active esters are nitrophenyl ester, pentafluorophenyl ester and N- hydroxysuccinimidyl ester.
  • oligonucleotides, DNA, R A, oligopeptides, proteins and lipids can be transformed statistically by using label molecules tethered to platinum derivatives. In nucleic acids these molecules react predominantly at N7 of guanine residues.
  • an exemplary reactive group A is
  • a ' is cleaving group selected from CI, (CH 3 ) 2 SO, H 2 0, and N0 3 wherein - is the position of the linker L.
  • the reactive group A is a polymerizable group, such as methacroyl group.
  • the chelate is to be attached to solid supports including nanomaterials, biomolecules, and various organic molecules using copper(I) catalyzed Huisgen-Sharpless dipolar [2+3] cycloaddition reaction, the reactive group A has to be either azide or terminal alkyne.
  • the reactive group A can be attached to the parent compound either directly or via a linker L.
  • the preferable position is the aromatic unit.
  • Exemplary positions are 3- and 4-positions of phenylethynyl unit.
  • the reactive group A is attached to 4-position of phenylethynyl group and it is selected from amino, isothiocyanate, iodoacetamido and 4,6- dichloro-l,3,5-triazin-2-ylamino groups.
  • the reactive groups are linked directly to the aromatic unit X are
  • the reactive group is attached to the parent compound via a liker L.
  • Exemplary positions are the pyridine unit, aromatic unit and the CH 2 units of the chelating part.
  • the preferable position of the linker is the aromatic unit.
  • the linker is preferable in applications wherein a space is needed between the chelate and the detectable molecule.
  • An exemplary linker L reactive group A combination is
  • Exemplary chelates according to the present technology has the chelating ligand of formula
  • the reactive group A is selected from amino, iodoacetamido, isothiocyanato and 4,6- dichloro-l,3,5-triazin-2-ylamino, and the lanthanide is selected from europium and samarium, preferably europium, and R a is selected from -CH 2 COO and -CH 2 CH 2 N(CH 2 COO ⁇ ) 2 . According to an embodiment, R a is CH 2 COO " .
  • Exemplary chelates according to the present technology have the chelating ligand of formula (IV) and wherein the reactive group A is selected from amino, iodoacetamido, isothiocyanato and 4,6-dichloro-l,3,5-triazin-2-ylamino, and carboxyl group, and the lanthanide is selected from terbium and dysprosium. According to an embodiment the lanthanide is terbium.
  • the present technology concerns a detectable molecule such as a biomolecule conjugated with a chelate according to the present technology.
  • the biomolecule is selected from the group consisting of oligopeptide, oligonucleotide, DNA, R A, modified oligo- or polynucleotide, protein, oligosaccharide, polysaccharide, phospholipide, PNA, LNA, antibody, antigen steroid, biotin, hapten, drug, receptor bindig ligand, and lectine.
  • the biomolecule can be labelled with the chelate of the present technology using methods known in the art.
  • the position of labelling and the number of chelates conjugated can be chosen by reaction conditions employed ad by choosing the reactive group A according to the demands of the application and the detectable molecule to be labelled.
  • R b is -(CH 2 ) m N(CH 2 COOR " ) 2 , wherein m is 2 or 3, and
  • R c is selected from CH 2 COOR", and -(CH 2 ) ! N(CH 2 COOR ' ' ) 2 , wherein 1 is 2 or 3 and wherein R" is a protecting group.
  • R is selected from -CH 2 COOR' ' and
  • the "parent compound2" is the part of the chelating ligand of formula (II) that is between the square brackets. Accordingly, the parent compound is understood as
  • the "aromatic unit” is a chemical compound that contains conjugated planar ring system with delocalized pi electron cloud instead of discrete alternating single and double bonds. It is obvious for a person skilled in art that if the aromatic unit of chelating agent of formula (II) includes one of more functional groups such as amines, carboxylic acids, alcohols, or mercapto groups they must be protected to avoid harmful side reactions during solid phase chain assembly. It is also obvious that the protecting group has to be chosen according to the solid phase chemistry to be used.
  • the chelating agents according to the present technology may include different protecting groups.
  • R " is aimed to protect the chelating carboxylic acid groups during solid phase synthesis of biomolecules such as oligonucleotides and oligopeptides.
  • R " is chosen according to the synthesis strategy employed. Most commonly R" is a permanent protecting group that is removed after completion of the chain assembly and before or during conversion of the biomolecule tethered to the chelating ligand to the corresponding lanthanide chelate.
  • Exemplary protecting groups R ' ' applicable to oligonucleotide and oligopeptide chemistries are base and acid labile esters, respectively.
  • the transient protecting groups are groups that are removed after each coupling step to allow chain elongation.
  • Exemplary transient protecting groups for oligopeptide and oligonucleotide chemistries are base labile carbamates and highly acid labile ethers, respectively.
  • the chelating agent according to this invention is suitable for use in the synthesis of an oligopeptide.
  • the reactive group A is connected to the chelating agent via a linker L, and A is a carboxylic acid or its salt, carboxylic acid halide or an ester or an amino acid residue -CH(NHR 1 )R 2 where R 1 is a transient protecting group and R 2 is a carboxylic acid or its salt, carboxylic acid halide or an ester.
  • a preferable halide is chloride.
  • the transient protecting group R 1 is selected from a group consisting of Fmoc (fluorenylmethoxycarbonyl), Boc (tert-butyloxycarbonyl), or Bsmoc (1,1- dioxobenzo[b]thiophen-2-ylmethyloxycarbonyl), and R 3 is a carboxylic acid or its salt, acid halide or an ester.
  • the protecting group R" is tert-butyl that can be removed with TFA.
  • the chelating agent can be introduced into detectable molecules such as biomolecules with the aid of a peptide synthesizer as disclosed e.g. in EP 0967205.
  • the chelating agent can be coupled to an amino tethered solid support or immobilized amino acid in the presence of an activator.
  • an activator e.g. an activator for activating the condensation step.
  • the transient amino protecting group of the chelating agent is selectively removed while the material is still attached to the solid support (e.g. with piperidine in the case of Fmoc-protecting group).
  • a second coupling of a chelating agent or other reagent e.g. appropriately protected amino acid, steroid, hapten or organic molecule
  • the material is detached from the solid support and deprotected.
  • the final cleavage and deptotection is performed by acid, such as TFA.
  • Purification can be performed by HPLC techniques.
  • the purified ligand is converted into the corresponding lanthanide(III) chelate by the addition of a known amount of lanthanide(III) ion.
  • Exemplary chelating agents of the present technology suitable for oligopeptide synthesis have the following structures:
  • the chelating agent according to the present technology is suitable for use in the synthesis of a labeled oligonucleotide on solid phase.
  • the reactive group A is connected to the chelating agent via a linker L, and A is-Z 1 -0-PZ 2 -0-R 3 wherein one of the oxygen atoms optionally is replaced by sulfur, Z 2 is chloro or NR 4 R 5 , R 3 is a protecting group, R 4 and R 5 are alkyl groups comprising 1-8 carbons, and Z 1 is absent or is a radical of a purine base or a pyrimidine base or any other modified base suitable for use in the synthesis of modified oligonucleotides.
  • the base is connected to the oxygen atom either via i) a hydrocarbon chain, which is substituted with a protected hydroxymethyl group, or via ii) a furan ring or pyrane ring or any modified furan or pyrane ring, suitable for use in the synthesis of modified oligonucleotides.
  • the chelating agent can be introduced into oligonucleotides with the aid of an oligonucleotide synthesizer.
  • a useful method is disclosed in US 6,949,639 and EP 1308452. These patent publications disclose a method for direct attachment of a desired number of conjugate groups to the oligonucleotide structure during chain assembly.
  • the chelating agents are introduced during the chain assembly. Conversion to the lanthanide chelate takes place after the synthesis during or after the deprotection steps.
  • the carboxylic acid protecting group R" is preferable a group that can be removed by treatment with base, such as hydroxide ion, ammonia and amine. Suitable protecting groups are methyl and ethyl groups.
  • Z 2 is a radical of any of the bases thymine, uracil, adenine, guanine or cytosine, and the base is connected to the oxygen atom via i) a hydrocarbon chain, which is substituted with a protected hydroxymethyl group, or via ii) a furan ring having a protected hydroxymethyl group in its 4-position and optionally a hydroxyl, protected hydroxyl or modified hydroxyl group in its 2-position.
  • the reactive group - Z 1 -0-P(NR 4 R 5 )-0-R 3 is selected from the group consisting of:
  • oligonucleotide conjugates tethered to a single label molecule Z 2 can be omitted from the structure.
  • exemplary chelating agents suitable for oligonucleotide synthesis have the following structures:
  • the biomolecule conjugated with a chelating agent or a chelate according to this invention is an oligopeptide, oligonucleotide, DNA, R A, modified oligo- or polynucleotide, such as phosphoromonothioate, phosphorodithioate, phosphoroamidate and/or sugar- or base modified oligo- or polynucleotide, protein, oligosaccaride, polysaccaride, phospholipide, PNA, LNA, antibody, steroid, hapten, drug, receptor binding ligand and lectine.
  • modified oligo- or polynucleotide such as phosphoromonothioate, phosphorodithioate, phosphoroamidate and/or sugar- or base modified oligo- or polynucleotide, protein, oligosaccaride, polysaccaride, phospholipide, PNA, LNA, antibody, steroid, hapten, drug, receptor
  • the present technology concerns a method of carrying out a specific bioaffinity assay using a biomolecule conjugated with a chelate of the present technology with an analyte to be determined.
  • the present technology concerns use of a biomolecules conjugated with the chelates of the present technology in a specific bioffinity binding assay utilizing fluorometric or time -resolved fluorometric determination of a specific luminescence.
  • the specific bioffinity assay is preferably selected from selected from a heterogenous immunoassay, a homogenous immunoassay, a DNA hydridization assay, a receptor binding assay, an immunological assay and an immunohistochemical assay.
  • the essential difference in the structure of the chelates prior art including a single pyridine subunit and the chelates of the present technology can be seen in Fig.l . Although there is no desire to be related to any theory, it is thought that the presence of additional carboxylic acid chelating groups enhance the stability and quantum yield compared to the chelates of the art comprising similar chromophore.
  • R 2 ⁇ [( ⁇ 2 ⁇ 2 ) ⁇ ( ⁇ 2 00 2 ' ⁇ ) 2 ] 2
  • Detection was performed with a Hamamatsu R928 photomultiplier. All spectra were corrected for the instrumental functions. When necessary, a 399 nm cut-off filter was used to eliminate the second order artifacts. Phosphorescence lifetimes were measured on the same instrument working in the phosphorescence mode, with 50 delay time and a 100 ms integration window. Emission decay profiles were fitted to mono-exponential and bi-exponential function using the FAST program from Edinburgh Instrument or with the Datastation software from Jobin Yvon.
  • the estimated relative error is ⁇ 1 %.
  • the isothiocyanates (la, 6a, 7a; 20 mg each) were allowed to react with glycine (300 mg) at pH ca 7.
  • the product was purified by HPLC (column: Supelco Ascentis RP -Amide, 21.2 mm • 25cm. Particle 5 ⁇ , flow rate 8.0 mL/min; eluent 20mM TEAA buffer in 2-25% acetonitrile, v/v). The fractions were collected and concentrated. The salts were removed on HPLC by using the above mentioned system by omitting the buffer component from the eluent.
  • HR-MS for lb C 26 H 22 EuN 5 Oi 0 S 2 ⁇ required 373.5148 and 374.5155, found 373.5163 and 374.5173.
  • the isothiocyanates (la, 6a, 7a; 1 mg each) were allowed to react with N-Biotinyl-3- aminopropylamine (TFA salt, 5 mg each) at pH ca 8.0.
  • the product was purified by HPLC (column: Supelco Ascentis RP -Amide, 4.6 mm x 15 cm, particle 5 ⁇ , flow rate 1.0 mL/min; eluent 20 mM TEAA buffer at pH 7.0 with 2-60% methanol, v/v). The fractions were collected and dried in vacuum.
  • the isothiocyate chelate 8a is synthesized as described above for 7a i.e. starting from 3, but using tetra-tert-butyl 2,2 ' ,2 " ,2 ' '-(azanediylbis(ethane-2, 1 -diyl))bis(azanetriyl))tetraacetate synthesized as disclosed in Bioconjugate Chem. 2008, 19, 1505-1509.
  • Example 10 Conditional stability constants determination.
  • the emission spectrum was measured and the decrease in intensity was fitted to equation (2) using the non-linear regression analysis of the SPECFIT software
  • conditional stability constant could be determined using values of ⁇ condEDTA calculated from literature data.
  • Example 1 1 hCRP immunoassay.
  • CRP Human C-reactive protein
  • 6404 monoclonal anti-CRP antibody 6404 was from Medix Biochemica (Kauniainen, Finland).
  • Nunc C12 low fluor maxi wells (Thermo Scientific, Roskilde, Denmark) were coated with 150 ng of 6404 antibody in 40 ⁇ 50 mM phosphate buffer pH 7.4 for 16 h at 4 °C.
  • the wells were washed twice using wash buffer from Kaivogen Oy (Turku, Finland). Final blocking of the well surface was carried out with 200 ⁇ 0.1 % BSA in the phophate buffer for 2 hours at 25 °C.
  • the same 6404 antibody was conjugated with ⁇ i-biotin NHS ester (Sigma-Aldrich, St. Louis, USA) using 20-fold excess in 50 mM phosphate buffer pH 7.8. After conjugation the antibody was purified with NAP-5 column (GE Healthcare, Uppsala, Sweden) using TBS- buffer (50 mM Tris-Cl pH 7.5, 150 mM NaCl). Three replicates of 0 - 10 mg/L hCRP were incubated for 60 min in 50 ⁇ of TBS-buffer in prewashed 6404 coated wells. The wells were washed once, and 50 ng of biotinylated 6404 antibody was added to the wells in 50 ⁇ of TBS and incubated for 60 min.
  • the wells were washed once and 50 ng streptavidin (BioSpa, Milan, Italy) in 50 ⁇ of TBS was added, incubated for 10 minutes and washed once. Thereafter, 50 ⁇ of 40 nM biotinylated europium chelates were added and incubated for 10 minutes.
  • the wells were washed twice and measured with a Victor 2 1420 multilabel counter (PerkinElmer, Wallac OY, Turku, Finland) in time -resolved luminescence mode using an excitation wavelength of 340 nm and an emission wavelength of 615 nm, a 400 ⁇ delay, and 400 ⁇ integration times.
  • Spectroscopic properties of the chelates The spectroscopic properties of the complexes were measured in 0.01 M TRIS/HCl buffer at pH 7.4 on the glycine functionalized complexes (lb, 6b, 7b), and the most important parameters are gathered in Table 1.
  • the UV-Vis absorption spectra of the three Eu complexes are very similar, displaying a strong absorption band centred at ca 318 nm, corresponding to ⁇ 3 ⁇ 4 transitions on the pyridyl rings (see Figure 2 for lb).
  • the presence of the /?ara-(thiourea)-toluyl substitution resulted in a strong bathochromic shift of this absorption band, when compared to non substituted pyridines for which the maximum of absorption can be found at 265-267 nm.
  • all complexes display well resolved emission bands between 575 and 730 nm associated to f-f transitions on the europium atom.
  • the complex obtained from the heptadentate ligand of lb displayed the shorter lifetime (0.39 ms), the coordination sphere of the europium being probably unsaturated. This was confirmed by the calculation of the hydration numbers of the complexes according to the method developed by Horrocks using Beeby's coefficients (Table 1). While the heptadentate ligand of lb releases the place for two inner sphere water molecules, the replacement of one or two acetate functions by iminodiacetate ones resulted in the fulfilment of the coordination sphere and the removal of solvent molecules from the first coordination sphere.
  • the Eu centred emission spectra of the complexes are presented in Figure 3. The 5 D 0 ⁇ 7 F 2 transition represents the most intense emission band.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Materials Engineering (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

This invention relates to a group of novel stable and luminescent lanthanide (III) chelates and chelating agents. This invention further relates to a detectable molecule comprising the lanthanide chelate and the use of the molecule in a method of carrying out a biospecific binding assay.

Description

CHELATES, CHELATING AGENTS, CONJUGATES DERIVED THEREOF AND THEIR
USE
FIELD
This invention relates to stable luminescent lanthanide(III) chelates and biomolecules labeled with these chelates. This invention further relates to the use of the chelates in a method of carrying out a biospecific binding assay. The invention relates also to chelating agents useful in solid phase synthesis of oligopeptides and oligonucleotides and oligopeptide and oligonucleotide conjugates so obtained.
BACKGROUND
Luminescent lanthanide(III) chelates have several special properties that make them excellent tools in especially homogenous bioaffinity assays. Their large Stokes' shift has a decreasing effect on scattering phenomena. The long fluorescence decay after excitation of these molecules allow time-resolved signal detection, which eliminates completely the background luminescence originating, e.g. from buffer components, plastics, and biomaterials. The very narrow emission lines allow the use of effective filters which diminish the background. Furthermore, since the lanthanide(III) chelates do not suffer from concentration quenching it is possible to have several chelates in close proximity enabling multilabeling. This phenomenom allows also the development of chelates bearing several light absorbing moieties.
However, the use of stable chelates in bioaffinity assays demands optimization of the chelate structure. The optimal luminescent lanthanide chelate must be stable in the presence of additional chelators even at low pH and high temperature. The chelate should have optimal emission profile, high hydrophilicity, small size, good biocompatibility, little effect on biomolecules and good energy transfer properties. In addition, the chelate should be feasible for different energy acceptors, and when possible, the synthesis of the molecule should be simple, cheap and scalable.
Europium(III) chelate of 4-[2-(4-isothiocyanatophenyl)ethynyl]-2,6,-bis{[N,N- bis(carboxymethyl)-amino]methyl}pyridine [US 4,920,195] is one of the most commonly used biomolecule labeling reagent, since it fulfills almost all of the above mentioned requirement. The most serious drawback of this chelate as well as other 7-dentate lanthanide(III) chelates is that it exhibits rather low chelate stability limiting its use in applications involving treatments at elevated temperature, low pH and in the presence of additional chelating agents such as EDTA.
The chelate stability can be increased by using cyclic chelating moieties [US 4,920,195; WO2005058877; WO2005021538] but neutralization of the net charge decreases the water solubility of the chelate. The decreased solubility of the cyclic chelates can be enhanced by using hydrophilic groups at the aromatic unit [WO2009030819]. The chelate stability can be enhanced also by increasing the number of chelating carboxylic acids [WO2008020113, US2004166585]. However, all the prior art methods for increasing chelate stability of chelates including pyridine subunit also increase the size of the chelate and/or decrease the chelate solubility.
SUMMARY
An object of the present technology is to alleviate and eliminate the problems related to the luminescent lanthanide chelates of prior art.
According to one aspect this technology concerns chelates including a lanthanide(III) ion selected from europium, terbium, samarium and dysprosium and a chelating ligand of formula
(I)
(I) wherein
X is an aromatic unit,
L is a linker formed from one to ten moieties, each moiety being selected from the group consisting of phenylene, alkylene containing 1-12 carbon atoms, ethynydiyl (-C≡C-), ethylenediyl (-C=C-), ether (-0-), thioether (-S-), amide (-CO-NH-, -CO-NR'-, -NH-CO- and -NR'-CO-), carbonyl (-CO-), ester (-COO- and -OOC-), disulfide (-SS-), sulfonamide (-S02- NH-, -S02-NR'-), sulfone (-S02-), phosphate (-0-P02-0-), diaza (-N=N-), and tertiary amine, wherein R' represents an alkyl group containing less than 5 carbon atoms, and L replacing a hydrogen anywhere in the parent compound, or not present,
A is a reactive group selected from isothiocyanate, bromoacetamido, iodoacetamido, maleimido, 4,6-dichloro-l,3,5-triazin-2-ylamino, pyridyldithio, thioester, aminooxy, azide, hydrazide, amino, alkyne, a methacroyl group, carboxylic acid, acid halide, and an active ester, wherein A' is cleaving group selected from CI, (CH3)2SO, H20, and N03 wherein - is the position of the linker L and
wherein - is the position of linker L, and A replacing a hydrogen of the aromatic unit X when the linker L is not present, and Ra is selected from -CH2COO and -(CH2)nN(CH2COO")2, wherein n is 2 or 3, and Rb is-(CH2)mN(CH2COO")2, wherein m is 2 or 3, and
Rc is selected from CH2COO-, and -(CH2)iN(CH2COO~)2, wherein 1 is 2 or 3. According to another aspect this technology concerns a chelating agent of formula II
wherein X is an aromatic unit, L is a linker formed from one to ten moieties, each moiety being selected from the group consisting of phenylene, alkylene containing 1-12 carbon atoms, ethynydiyl (-C≡C-), ethylenediyl (-C=C-), ether (-0-), thioether (-S-), amide (-CO-NH-, -CO-NR'-, -NH-CO- and -NR'-CO-), carbonyl (-CO-), ester (-COO- and -OOC-), disulfide (-SS-), sulfonamide (-S02- NH-, -S02-NR'-), sulfone (-S02-), phosphate (-0-P02-0-), diaza (-N=N-), and tertiary amine, wherein R' represents an alkyl group containing less than 5 carbon atoms and replacing a hydrogen anywhere in the parent compound2,
A is a reactive group selected from the group consisting of carboxylic acid or its salt, acid halide, carboxylic acid ester, an amino acid residue -CH(NHR1)R2 where R1 is a transient protecting group and R2 is a carboxylic acid or its salt, carboxylic acid halide or an active ester and a group of -Z1-0-PZ2-0-R3 where one or two of the oxygen atoms optionally is replaced by sulfur, Z2 is chloro or NR4R5, R3 is a protecting group, R4 and R5 are alkyl groups including 1-8 carbons, Z1 is absent or is a radical of a purine base or a pyrimidine base wherein the base is connected to the oxygen atom via either a) a hydrocarbon chain, which is substituted with a protected hydroxymethyl group, or b) a furan ring or pyrane ring, and Rd is selected from -CH2COOR" and -(CH2)nN(CH2COOR")2, wherein n is 2 or 3,
Re is -(CH2)mN(CH2COOR")2, whereinm is 2 or 3, and
Rf is selected from CH2COOR", and -(CH2)1N(CH2C00R")2, wherein 1 is 2 or 3 and wherein R" is a protecting group. According to another aspect this technology concerns a detectable molecule such as a biomolecule conjugated with a chelate according the present technology wherein the biomolecule is selected from the group consisting of oligopeptide, oligonucleotide, DNA, RNA, modified oligo- or polynucleotide, protein, oligosaccharide, polysaccharide, phospholipide, PNA, LNA, antibody, antigen, steroid, biotin, hapten, drug, receptor bindig ligand, and lectine.
According to another aspect this technology concerns a detectable molecule such as a biomolecule obtained by synthesis on a solid phase by introduction of a chelating agent according to the present technology into the biomolecule structure followed by deprotection and introduction of a lanthanide ion. According to another aspect the present technology concerns a method of carrying out a specific bioaffinity assay using a biomolecule conjugate of the present technology with an analyte to be determined. According to another aspect the present technology concerns a use of a biomolecule conjugate according to the present technology in a specific bioaffinity binding assay utilizing fluorometric or time -resolved fluorometric determination of a specific luminescence.
Further aspects of the present technology have been disclosed in dependent claims.
BRIEF DESCRIPTION OF DRAWINGS
Figure 1 discloses the structures of the chelate of prior art (1) and two representative chelates according to the present technology (6,7).
Figure 2 discloses UV-Vis absorption, excitation kem = 615 nm) and emission ( exc = 319 nm) spectra of lb in 0.01 M TRIS/HCl buffer at pH 7.4.
Figure 3 discloses emission spectra of the lb, 6b and 7b complexes (from bottom to top) in TRIS/HCl buffer (0.01 M, pH 7.4; Aexc = 318 nm).
Figure 4 discloses hCRP immunoassays with biotin-conjugated europium chelates: lc (■), 6c (·), and 7c (A). The lower limit of detections for the biotin chelates were 6.5, 1.5 and 1.9 μg/L, respectively.
DETAILED DESCRIPTION
In this invention, it was observed that stability of a lanthanide chelate including a pyridine subunit can be enhanced without need to increase significantly the size of the chelating ligand. According to one embodiment, the present technology concerns chelates including a lanthanide(III) ion selected from europium, terbium, samarium and dysprosium and a chelating ligand of formula (I)
(I) wherein
X is an aromatic unit,
L is a linker formed from one to ten moieties, each moiety being selected from the group consisting of phenylene, alkylene containing 1-12 carbon atoms, ethynydiyl (-C≡C-), ethylenediyl (-C=C-), ether (-0-), thioether (-S-), amide (-CO-NH-, -CO-NR'-, -NH-CO- and -NR'-CO-), carbonyl (-CO-), ester (-COO- and -OOC-), disulfide (-SS-), sulfonamide (-S02- NH-, -S02-NR'-), sulfone (-S02-), phosphate (-0-P02-0-), diaza (-N=N-), and tertiary amine, wherein R' represents an alkyl group containing less than 5 carbon atoms, and L replacing a hydrogen anywhere in the parent compound or not present, A is a reactive group selected from isothiocyanate, bromoacetamido, iodoacetamido, maleimido, 4,6-dichloro-l,3,5-triazin-2-ylamino, pyridyldithio, thioester, aminooxy, azide, hydrazide, amino, alkyne, a methacroyl group, carboxylic acid, acid halide, and an active ester, wherein A' is cleaving group selected from CI, (CH3)2SO, H20, and N03 wherein - is the position of the linker L and
wherein - is the position of linker L, and A replacing a hydrogen of the aromatic unit X when the linker L is not present, and Ra is selected from -CH2COO and -(CH2)nN(CH2COO")2, wherein n is 2 or 3, and Rb is-(CH2)mN(CH2COO")2, wherein m is 2 or 3, and
Rc is selected from CH2COO-, and -(CH2)1N(CH2COO")2, wherein m is 2 or 3.
According to a preferable embodiment Ra is selected from -CH2COO" and
-CH2CH2N(CH2COO~)2, Rb is -(CH2)2N(CH2COO")2, and Rc is CH2COO . According to this embodiment the chelates of the present technology have the following structures
Wherein X, L and A are as defined above, and Ln is selected from Eu, Tb, Sm, and Dy.
As defined herein, the "parent compound" is the part of the chelating ligand of formula (I) that is between the square brackets. Accordingly, the parent compound is understood as
As defined herein, the "aromatic unit" is a chemical compound that contains conjugated planar ring system with delocalized pi electron cloud instead of discrete alternating single and double bonds. Exemplary aromatic units suitable for the present technology are phenylethynyl, furyl, thienyl, phenyl, and pyrrole groups, and their substituted derivatives. Exemplary substituents are alkyl groups and alkoxy groups. Methods to synthesize the pyridines with an aromatic group X are known in the art. Exemplary methods are disclosed in Bioconjugate Chemistry, 2009, vol 20, page 405, Scheme 1, incorporated here by reference.
As defined herein, "alkyl group" is linear or branched, like methyl, ethyl, /? -propyl, /-propyl, /? -butyl, /-butyl and sec -butyl group. The alkyl group can be tethered also to other groups like hydroxyl, carboxylic acid, carbohydrate and sulfonic acid groups.
As defined herein "alkoxy group" can be linear or branched, like methoxy, ethoxy, n- propoxy, /-propoxy, n-butoxyl, /-butoxyl and sec-butoxy group. The alkoxy group can be tethered also to other groups like hydroxyl, carbohydrate, carboxylic acid and sulfonic acid groups. Exemplary alkoxy and alkyl substituted aromatic units are wherein - is the position of wherein the aromatic unit is connected to the pyridine unit and wherein -CH2COOH and -COOH groups are exemplary reactive groups A.
The aromatic unit is connected to 3- or preferably to 4-position of the pyridine unit. The chelate must bear a reactive group A in order to enable covalent binding to a detectable molecule such as to a biomolecule.
According to an embodiment, the reactive group A is selected from the group consisting isothiocyanate, bromoacetamido, iodoacetamido, maleimido, 4,6-dichloro-l,3,5-triazin-2- ylamino, pyridyldithio, thioester, aminooxy, azide, hydrazide, amino, alkyne, a polymerizable group such as methacroyl group, and a carboxylic acid or carboxylic acid halide or an active ester thereof. As defined herein "active ester" is an aryl ester, vinyl ester, or hydroxyamine ester. Exemplary active esters are nitrophenyl ester, pentafluorophenyl ester and N- hydroxysuccinimidyl ester.
It has been proposed [U.S. 5,985,566] that oligonucleotides, DNA, R A, oligopeptides, proteins and lipids can be transformed statistically by using label molecules tethered to platinum derivatives. In nucleic acids these molecules react predominantly at N7 of guanine residues. When the chelates of the present technology are used for these labelling purposes an exemplary reactive group A is
wherein A' is cleaving group selected from CI, (CH3)2SO, H20, and N03 wherein - is the position of the linker L.
When the chelate of the present technology is used for bioconjugation of phosphodiester linkages an exemplary reactive group A is
wherein - is the position of linker L.
In case the chelate should be attached to a microparticle or nanoparticle during the manufacturing process of said particles, the reactive group A is a polymerizable group, such as methacroyl group. In the case the chelate is to be attached to solid supports including nanomaterials, biomolecules, and various organic molecules using copper(I) catalyzed Huisgen-Sharpless dipolar [2+3] cycloaddition reaction, the reactive group A has to be either azide or terminal alkyne.
The reactive group A can be attached to the parent compound either directly or via a linker L. When the reactive group is attached to the parent compound directly, the preferable position is the aromatic unit. Exemplary positions are 3- and 4-positions of phenylethynyl unit. According to a preferable embodiment the reactive group A is attached to 4-position of phenylethynyl group and it is selected from amino, isothiocyanate, iodoacetamido and 4,6- dichloro-l,3,5-triazin-2-ylamino groups. According to exemplary embodiments wherein the reactive groups are linked directly to the aromatic unit X are
wherein - is the position of pyridine unit and the aromatic unit is phenylethynyl group.
According to one embodiment the reactive group is attached to the parent compound via a liker L. The linker is formed from one to ten moieties, each moiety being selected from the group consisting of phenylene, alkylene containing 1-12 carbon atoms, ethynydiyl (-C≡C-), ethylenediyl (-C=C-), ether (-0-), thioether (-S-), amide (-CO-NH-, -CO-NR'-, -NH-CO- and -NR'-CO-), carbonyl (-CO-), ester (-COO- and -OOC-), disulfide (-SS-), sulfonamide (-S02- NH-, -S02-NR'-), sulfone (-S02-), phosphate (-0-P02-0-), diaza (-N=N-), and tertiary amine, wherein R' represents an alkyl group containing less than 5 carbon atoms and replacing a hydrogen anywhere in the parent compound. Exemplary positions are the pyridine unit, aromatic unit and the CH2 units of the chelating part. The preferable position of the linker is the aromatic unit. The linker is preferable in applications wherein a space is needed between the chelate and the detectable molecule. An exemplary linker L reactive group A combination is
wherein - is the position of the pyridine unit.
Although organic chelators and their substituents have a significant effect on the photophysical properties of lanthanide(III) chelates, no general rules for the estimation of these effects are available. It has been proposed [US 4,761,481] that electron releasing substituents in the aromatic moiety of phenyl and naphthyl substituted 2,6-[N,N- di(carboxyalkyl)aminoalkyl]pyridines have advantageous effects on the photophysical properties on their chelates with lanthanide ions. However, no experimental evidence was given. Later it has been shown that this is the case with various terbium(III) and dysprosium(III) chelates [U.S. patent application Ser. No. 11/004,061] but the corresponding europium(III) chelates are practically non-luminescent [Hemmila et al., J. Biochem. Biophys. Methods, 1993, 26, 283]. Accordingly, it is clear for a person skilled in art that the choose of the lanthanide ion depends on the nature of the chromophore.
Exemplary chelates according to the present technology has the chelating ligand of formula
(III)
wherein the reactive group A is selected from amino, iodoacetamido, isothiocyanato and 4,6- dichloro-l,3,5-triazin-2-ylamino, and the lanthanide is selected from europium and samarium, preferably europium, and Ra is selected from -CH2COO and -CH2CH2N(CH2COO~)2. According to an embodiment, Ra is CH2COO".
It is apparent that although the chelating carboxylic acid groups of the chelating ligands of formulas of this disclosure, such as formula (I) and formula (III), are drawn as deprotonated (i.e. -COO"), the formulas are only illustrative and the scope of the invention covers chelating ligands wherein one or more of the carboxylic acid groups are protonated (i.e. -COOH). Exemplary chelates according to the present technology have the chelating ligand of formula (IV) and wherein the reactive group A is selected from amino, iodoacetamido, isothiocyanato and 4,6-dichloro-l,3,5-triazin-2-ylamino, and carboxyl group, and the lanthanide is selected from terbium and dysprosium. According to an embodiment the lanthanide is terbium.
According to another embodiment the present technology concerns a detectable molecule such as a biomolecule conjugated with a chelate according to the present technology. The biomolecule is selected from the group consisting of oligopeptide, oligonucleotide, DNA, R A, modified oligo- or polynucleotide, protein, oligosaccharide, polysaccharide, phospholipide, PNA, LNA, antibody, antigen steroid, biotin, hapten, drug, receptor bindig ligand, and lectine. The biomolecule can be labelled with the chelate of the present technology using methods known in the art. The position of labelling and the number of chelates conjugated can be chosen by reaction conditions employed ad by choosing the reactive group A according to the demands of the application and the detectable molecule to be labelled.
According to another embodiment this technology concerns a chelating agent of formula II
(II) wherein X is an aromatic unit,
L is a linker formed from one to ten moieties, each moiety being selected from the group consisting of phenylene, alkylene containing 1-12 carbon atoms, ethynydiyl (-C≡C-), ethylenediyl (-C=C-), ether (-0-), thioether (-S-), amide (-CO-NH-, -CO-NR'-, -NH-CO- and -NR'-CO-), carbonyl (-CO-), ester (-COO- and -OOC-), disulfide (-SS-), sulfonamide (-S02- NH-, -S02-NR'-), sulfone (-S02-), phosphate (-0-P02-0-), diaza (-N=N-), and tertiary amine, wherein R' represents an alkyl group containing less than 5 carbon atoms and replacing a hydrogen anywhere in the parent compound2, A is a reactive group selected from the group consisting of carboxylic acid or its salt, acid halide, carboxylic acid ester, an amino acid residue -CH(NHR1)R2 where R1 is a transient protecting group and R2 is a carboxylic acid or its salt, carboxylic acid halide or an active ester and a group of -Z1-0-PZ2-0-R3 where one or two of the oxygen atoms optionally is replaced by sulfur, Z2 is chloro or NR4R5, R3 is a protecting group, R4 and R5 are alkyl groups including 1-8 carbons, Z1 is absent or is a radical of a purine base or a pyrimidine base wherein the base is connected to the oxygen atom via either a) a hydrocarbon chain, which is substituted with a protected hydroxymethyl group, or b) a furan ring or pyrane ring, and Rd is selected from -CH2COOR" and -(CH2)nN(CH2COOR")2, wherein n is 2 or 3,
Rb is -(CH2)mN(CH2COOR")2, wherein m is 2 or 3, and
Rc is selected from CH2COOR", and -(CH2)!N(CH2COOR' ')2, wherein 1 is 2 or 3 and wherein R" is a protecting group.
According to a preferable embodiment R is selected from -CH2COOR' ' and
-CH2CH2N(CH2COOR")2, Rb is -(CH2)2N(CH2COOR ")2, and Rc is CH2COOR" As defined herein, the "parent compound2" is the part of the chelating ligand of formula (II) that is between the square brackets. Accordingly, the parent compound is understood as
As defined herein, the "aromatic unit" is a chemical compound that contains conjugated planar ring system with delocalized pi electron cloud instead of discrete alternating single and double bonds. It is obvious for a person skilled in art that if the aromatic unit of chelating agent of formula (II) includes one of more functional groups such as amines, carboxylic acids, alcohols, or mercapto groups they must be protected to avoid harmful side reactions during solid phase chain assembly. It is also obvious that the protecting group has to be chosen according to the solid phase chemistry to be used.
The chelating agents according to the present technology may include different protecting groups. R" is aimed to protect the chelating carboxylic acid groups during solid phase synthesis of biomolecules such as oligonucleotides and oligopeptides. R" is chosen according to the synthesis strategy employed. Most commonly R" is a permanent protecting group that is removed after completion of the chain assembly and before or during conversion of the biomolecule tethered to the chelating ligand to the corresponding lanthanide chelate. Exemplary protecting groups R' ' applicable to oligonucleotide and oligopeptide chemistries are base and acid labile esters, respectively. The transient protecting groups are groups that are removed after each coupling step to allow chain elongation. Exemplary transient protecting groups for oligopeptide and oligonucleotide chemistries are base labile carbamates and highly acid labile ethers, respectively.
According to one embodiment, the chelating agent according to this invention is suitable for use in the synthesis of an oligopeptide. In this application, the reactive group A is connected to the chelating agent via a linker L, and A is a carboxylic acid or its salt, carboxylic acid halide or an ester or an amino acid residue -CH(NHR1)R2 where R1 is a transient protecting group and R2 is a carboxylic acid or its salt, carboxylic acid halide or an ester. A preferable halide is chloride.
In a preferable embodiment the transient protecting group R1 is selected from a group consisting of Fmoc (fluorenylmethoxycarbonyl), Boc (tert-butyloxycarbonyl), or Bsmoc (1,1- dioxobenzo[b]thiophen-2-ylmethyloxycarbonyl), and R3 is a carboxylic acid or its salt, acid halide or an ester. In a preferable embodiment the protecting group R" is tert-butyl that can be removed with TFA.
The chelating agent can be introduced into detectable molecules such as biomolecules with the aid of a peptide synthesizer as disclosed e.g. in EP 0967205. The chelating agent can be coupled to an amino tethered solid support or immobilized amino acid in the presence of an activator. When the condensation step is completed the transient amino protecting group of the chelating agent is selectively removed while the material is still attached to the solid support (e.g. with piperidine in the case of Fmoc-protecting group). Then, a second coupling of a chelating agent or other reagent (e.g. appropriately protected amino acid, steroid, hapten or organic molecule) is performed as above. When the synthesis of the desired molecule is completed, the material is detached from the solid support and deprotected. In Fmoc chemistry, the final cleavage and deptotection is performed by acid, such as TFA. Purification can be performed by HPLC techniques. Finally, the purified ligand is converted into the corresponding lanthanide(III) chelate by the addition of a known amount of lanthanide(III) ion.
Exemplary chelating agents of the present technology suitable for oligopeptide synthesis have the following structures:
According to another embodiment, the chelating agent according to the present technology is suitable for use in the synthesis of a labeled oligonucleotide on solid phase. In this case the reactive group A is connected to the chelating agent via a linker L, and A is-Z1-0-PZ2-0-R3 wherein one of the oxygen atoms optionally is replaced by sulfur, Z2 is chloro or NR4R5, R3 is a protecting group, R4 and R5 are alkyl groups comprising 1-8 carbons, and Z1 is absent or is a radical of a purine base or a pyrimidine base or any other modified base suitable for use in the synthesis of modified oligonucleotides. The base is connected to the oxygen atom either via i) a hydrocarbon chain, which is substituted with a protected hydroxymethyl group, or via ii) a furan ring or pyrane ring or any modified furan or pyrane ring, suitable for use in the synthesis of modified oligonucleotides.
The chelating agent can be introduced into oligonucleotides with the aid of an oligonucleotide synthesizer. A useful method is disclosed in US 6,949,639 and EP 1308452. These patent publications disclose a method for direct attachment of a desired number of conjugate groups to the oligonucleotide structure during chain assembly. The chelating agents are introduced during the chain assembly. Conversion to the lanthanide chelate takes place after the synthesis during or after the deprotection steps. The carboxylic acid protecting group R" is preferable a group that can be removed by treatment with base, such as hydroxide ion, ammonia and amine. Suitable protecting groups are methyl and ethyl groups.
According to one embodiment Z2 is a radical of any of the bases thymine, uracil, adenine, guanine or cytosine, and the base is connected to the oxygen atom via i) a hydrocarbon chain, which is substituted with a protected hydroxymethyl group, or via ii) a furan ring having a protected hydroxymethyl group in its 4-position and optionally a hydroxyl, protected hydroxyl or modified hydroxyl group in its 2-position.
According to one embodiment the reactive group - Z1-0-P(NR4R5)-0-R3 is selected from the group consisting of:
wherein - is the position of the linker L and DMTr is dimethoxytrityl.
For the preparation of oligonucleotide conjugates tethered to a single label molecule Z2 can be omitted from the structure. Exemplary chelating agents suitable for oligonucleotide synthesis have the following structures:
The biomolecule conjugated with a chelating agent or a chelate according to this invention is an oligopeptide, oligonucleotide, DNA, R A, modified oligo- or polynucleotide, such as phosphoromonothioate, phosphorodithioate, phosphoroamidate and/or sugar- or base modified oligo- or polynucleotide, protein, oligosaccaride, polysaccaride, phospholipide, PNA, LNA, antibody, steroid, hapten, drug, receptor binding ligand and lectine.
According to another embodiment the present technology concerns a method of carrying out a specific bioaffinity assay using a biomolecule conjugated with a chelate of the present technology with an analyte to be determined.
According to another embodiment the present technology concerns use of a biomolecules conjugated with the chelates of the present technology in a specific bioffinity binding assay utilizing fluorometric or time -resolved fluorometric determination of a specific luminescence. The specific bioffinity assay is preferably selected from selected from a heterogenous immunoassay, a homogenous immunoassay, a DNA hydridization assay, a receptor binding assay, an immunological assay and an immunohistochemical assay. The essential difference in the structure of the chelates prior art including a single pyridine subunit and the chelates of the present technology can be seen in Fig.l . Although there is no desire to be related to any theory, it is thought that the presence of additional carboxylic acid chelating groups enhance the stability and quantum yield compared to the chelates of the art comprising similar chromophore.
The invention will be illuminated by the following non-restrictive examples.
EXAMPLES The synthetic routes employed in the experimental part are depicted in Scheme 1. Formulas of compounds 6a-c and 7a-c are shown in Figure 1.
R2 = Ν[(ΟΗ2ΟΗ2)Ν(ΟΗ2002'Βυ)2]2
Scheme 1 Experimental Procedures
All reagents and solvents used were of reagent grade. The 1H and 13C NMR spectra were recorded on a Bruker Avance 600 MHz NMR spectrometer operating at 600.1337 MHz and 150.9179 MHz for 1H and 13C, respectively. HR Mass spectra were recorded on a Bruker micrOTOF-Q mass spectrometer. UV -visible absorption spectra were recorded on a Specord 205 (Analytik Jena) spectrometer. Steady state emission and excitation spectra were recorded on a Horiba Jobin Yvon Fluorolog 3 spectrometer working with a continuous 450W Xe lamp. Detection was performed with a Hamamatsu R928 photomultiplier. All spectra were corrected for the instrumental functions. When necessary, a 399 nm cut-off filter was used to eliminate the second order artifacts. Phosphorescence lifetimes were measured on the same instrument working in the phosphorescence mode, with 50 delay time and a 100 ms integration window. Emission decay profiles were fitted to mono-exponential and bi-exponential function using the FAST program from Edinburgh Instrument or with the Datastation software from Jobin Yvon. Hydrations numbers, q, were obtained using equation (1), were ¾2o and ¾2ο respectively refer to the measured luminescence decay lifetimes (in ms) in water and deuterated water, using AEu= 1.2 and aEu= 0.25 for Euin:
Luminescence quantum yields were measured according to conventional procedures, with diluted solutions (optical density <0.05), using [Ru(bipy)3]Cl2 in nondegassed water (Φ= 4.0%) as reference. The estimated relative error is ± 1 %.
Example 1.
Synthesis of Tetra-tert-butyl 2,2',2",2"'-{ { {[(4-bromopyridine-2,6-diyl)bis(methylene)]bis([2- (tert-butoxy)-2-oxoethyl]azanediyl} }bis(ethane-2, 1 -diyl)}bis(azanetriyl)} tetraacetate (4a).
A mixture of 4-bromo-2,6-bis(bromomethyl)pyridine (2; 344 mg, 1.0 mmol), tert- butyl{[bis(tert-butoxycarbonyl methyl)aminoethyl] amino }tris(acetate) (843 mg, 2.10 mmol) and dry potassium carbonate (1.38 g, 10 mmol) in dry acetonitrile (50 mL) was stirred overnight at 55°C. The solid was removed by filtration. The solvent was evaporated in vacuo and the product was purified on a silica gel column using 1% (v/v) triethylamine in dichloromethane as the eluent. Yield was 0.56 g (57%). 1H NMR (CDC13): δ 7.59 (s, 2H),
3.79 (br, 4H), 3.39 (s, 8H), 3.33 (br, 4H), 2.84 (br, 8H), 1.40 (s, 18H), 1.38 (s, 36H). I3C NMR (CDC13): δ 170.48, 160.79, 134.32, 124.09, 80.88, 59.79, 56.05, 53.40, 52.63, 52.06, 28.12, 28.10. HR-MS for C47H8iBrN50i2 +: required 986.5060 and 988.5040, found 986.4993 and 988.4985.
Example 2
Synthesis of di-tert-butyl 2,2'-{ { {6-{ { {2-(bis[2-(tert-butoxy)-2-oxoethyl]amino}ethyl} [2- (tert-butoxy)-2-oxoethyl]amino}methyl} -4-bromopyridin-2-yl}methyl} azanediyl} diacetate
(4b).
Di-tert-butyl 2,2'-{[4-bromo-6-(bromomethyl)pyridin-2-yl]methylenenitrilo}bis(acetate) (3) (385 mg, 0.76 mmol), tert-butyl{[bis(tert-butoxycarbonylmethyl)aminoethyl] amino} acetate (319 mg, 0.80 mmol) and potassium carbonate (dry) (524 mg, 3.80 mmol) was stirred overnight at 55°C. The solid was removed by filtration. The solvent was evaporated in vacuo and the product was purified on a silica gel column using 20% (v/v) of ethyl acetate in petroleum ether as the eluent. Yield was 562 mg (89%). 1H NMR (CDC13): δ 7.69 (s, 1H), 7.59 (s, 1H), 3.94 (s, 4H), 3.41 and 3.40 (2s, 10H), 2.86 (br s, 4H), 1.41 (s, 27H), 1.38 (s, 18H). 13C NMR (CDC13): δ 170.45, 170.29, 160.60, 134.49, 124.39, 124.26, 81.10, 81.00, 59.65, 59.42, 56.01 , 55.81 , 52.64, 51.88, 28.13, 28.1 1. HR-MS for C39H66BrN4Oio+: required 829.3957 and 831.3937, found 829.4050 and 831.4038.
Example 3.
Synthesis of tetra-tert-butyl 2,2',2",2"'-(((((4-((4-aminophenyl)ethynyl)pyridine-2,6-diyl) bis(methylene))bis((2-(tert-butoxy)-2-oxoethyl)azanediyl))bis(ethane-2,l-diyl))
bis(azanetriyl))-tetraacetate (5a)
Compound 4a (364 mg, 0.37 mmol) and 4-ethynylaniline (52 mg, 0.44 mmol) in the mixture of THF (10 mL) and DIPEA (10 mL) was deaerated with nitrogen for 5 min. Pd(PPh3)2Cl2 (10.4 mg, 0.015 mmol) and Cul (2.9 mg, 0.015 mmol) were added as the catalysts, and the reaction mixture was stirred overnight under nitrogen at 60°C. The solvents were removed in vacuo and the product was purified on a silica gel column using a mixture of 20-30%) (v/v) of ethyl acetate in petroleum ether containing 1% (v/v) triethylamine as the eluent. Yield was 290 mg (76%). 1H NMR (CDC13, 50°C): δ 7.44 (s, 2H), 7.30 (d, J=8.45 Hz, 2H), 6.61 (d, j=8.50 Hz, 2H), 3.96 (br s, 4H), 3.43 (s, 8H), 3.40 (br s, 4H), 2.90 (b, 8H), 1.46 (s, 18H), 1.42 (s, 36H). 13C NMR (CDC13, 50°C): δ 170.55, 158.78, 147.56, 133.32, 132.57, 122.66, 1 14.54, 1 1 1.47, 85.87, 80.83, 80.75, 60.07, 56.24, 52.88, 52.47, 28.17, 28.13. HR-MS for C55H87N6Oi2+: required 1023.6376, found 1023.6308.
Example 4.
Synthesis of di-tert-butyl 2,2'-(((4-((4-aminophenyl)ethynyl)-6-(((2-(bis(2-(tert-butoxy)-2- oxoethyl)amino)-ethyl)(2-(tert-butoxy)-2-oxoethyl)amino)methyl)pyridin-2- yl)methyl)azanediyl)diacetate (5b)
The synthesis was performed as above for compound 5a but using 4b (562 mg, 0.68 mmol) as the starting material. Yield was 421 mg (72%). 1H NMR (CDC13): δ 7.45 (s, 1H), 7.35 (s, 1H), 7.18 (d, J=8.46 Hz, 2H), 6.51 (d, J=8.52 Hz, 2H), 4.17 (br s, 2H), 3.91 (s, 2H), 3.81 (s, 2H), 3.38 (s, 4H), 3.35 (s, 4H), 3.27 (s, 2H), 2.77 (t, d, J=6.54, 25.21 Hz, 4H), 1.37 (s, 27H), 1.33 (s, 18H). 13C NMR (CDC13): δ 170.68, 170.55, 170.38, 159.06, 158.64, 147.93, 133.18, 133.15, 122.47, 122.38, 1 14.38, 1 10.70, 94.80, 85.66, 80.89, 80.72, 80.70, 60.21 , 60.08, 59.63, 56.14, 56.09, 55.71 , 52.55, 52.16, 28.09, 28.07, 28.04. HR-MS for C47H72N5Oio+: required 866.5274, found 866.5294.
Example 5.
Preparation of the complex 6a. Compound 5b (220 mg, 0.215 mmol) was dissolved in TFA (2 mL) and the mixture was stirred in a water-bath at 25°C for 2 hours. All volatiles were removed in vacuo. The residue was dissolved in water (2 mL), a EuCl3 solution (0.236 mmol in 0.5 mL water) was added and stirred for 10 min. The pH was adjusted to 7.0 with triethylamine and the mixture was stirred for another 10 minutes. The pH was adjusted to 9.0 with sat. Na2C03. The precipitate formed was removed by centrifugation. The pH of the solution was adjusted to 7.0 with acetic acid. Acetone (45 mL) was added and the mixture was shaken for 1 min. The precipitate was collected by centrifugation, washed with acetone (50 mL) and dried with airflow. HR-MS for C27H27EuN5Oio": required 732.0961 and 734.0975, found 732.1024 and 734.1032. The precipitate was dissolved in water (1 mL). Chloroform (1 mL) and thiophosgene (0.33 mL, 4.3 mmol) were added and the mixture was stirred vigorously for 5 minutes. The pH was monitored and kept at 7.0 with 15% of NaHC03 solution. Chloroform was removed followed by addition of acetone (50 mL) with stirring. The precipitate formed was isolated by centrifugation, washed with acetone (50 mL) and dried. HR-MS for
required 774.0526 and 776.0539, found 774.0649 and 776.0694. Example 6.
Preparation of complex 7a
The title compound was prepared as described above for compound 6a but using compound 5a (234 mg, 0.27 mmol) as the starting material. HR-MS for the amino form C3iH33EuNeOi2 2" : required 416.0683 and 417.0690, found 416.0721 and 417.0740. HR-MS for the isothiocyanato form C32H3iEuN6Oi2S2": required 437.0465 and 438.0472, found 437.0521 and 438.0512.
Example 7.
Preparation of glycine-complexes lb, 6b and 7b.
The isothiocyanates (la, 6a, 7a; 20 mg each) were allowed to react with glycine (300 mg) at pH ca 7. The product was purified by HPLC (column: Supelco Ascentis RP -Amide, 21.2 mm • 25cm. Particle 5μιη, flow rate 8.0 mL/min; eluent 20mM TEAA buffer in 2-25% acetonitrile, v/v). The fractions were collected and concentrated. The salts were removed on HPLC by using the above mentioned system by omitting the buffer component from the eluent. HR-MS for lb C26H22EuN5Oi0S2~: required 373.5148 and 374.5155, found 373.5163 and 374.5173.
HR-MS for 6b C30H29EuN6Oi2S2~: required 424.0387 and 425.0393, found 424.0398 and 425.0380.
HR-MS for 7b C34H36EuN7Oi4S2~: required 474.5625 and 475.5632, found 474.5676 and 475.5690.
Example 8.
Preparation of Biotin-complexes of lc, 6c and 7c.
The isothiocyanates (la, 6a, 7a; 1 mg each) were allowed to react with N-Biotinyl-3- aminopropylamine (TFA salt, 5 mg each) at pH ca 8.0. The product was purified by HPLC (column: Supelco Ascentis RP -Amide, 4.6 mm x 15 cm, particle 5μιη, flow rate 1.0 mL/min; eluent 20 mM TEAA buffer at pH 7.0 with 2-60% methanol, v/v). The fractions were collected and dried in vacuum.
HR-MS for lc C37H4iEuN8Oi0S2 2~: required 486.0798 and 487.0805, found 486.0764 and 487.0780.
HR-MS for 6c C4iH48EuN9Oi2S2 2": required 536.6037 and 537.6044, found 536.6014 and 537.6023.
HR-MS for 7c C45H55EuNi0Oi4S2 2": required 587.1275 and 588.1282, found 587.1251 and
588.1260.
Example 9 Preparation of the complex 8a
The isothiocyate chelate 8a is synthesized as described above for 7a i.e. starting from 3, but using tetra-tert-butyl 2,2 ' ,2 " ,2 ' '-(azanediylbis(ethane-2, 1 -diyl))bis(azanetriyl))tetraacetate synthesized as disclosed in Bioconjugate Chem. 2008, 19, 1505-1509.
Example 10. Conditional stability constants determination. In a typical experiment batches of 2 mL of ca 2x 10~5 M solutions of the europium complexes in TRIS buffer at pH = 7.4 were mixed with various quantities of a stock solution of 5X 10~2 M EDTA (or DOT A) in the same buffer, so that the ratio of added EDTA per Eu complex varies from 0 to 450000. For each solution, the emission spectrum was measured and the decrease in intensity was fitted to equation (2) using the non-linear regression analysis of the SPECFIT software
[EuL] + EDTA <→ [Eu(EDTA)] + L (2)
[Eu(EDTA)] x [L] _ KcondEDTA
with K
[EDTA] X [EUL] KT
The conditional stability constant could be determined using values of ^condEDTA calculated from literature data.
Example 1 1 hCRP immunoassay.
Human C-reactive protein (CRP) was obtained from (Orion Diagnostica, Espoo, Finland) and monoclonal anti-CRP antibody 6404 was from Medix Biochemica (Kauniainen, Finland). Nunc C12 low fluor maxi wells (Thermo Scientific, Roskilde, Denmark) were coated with 150 ng of 6404 antibody in 40 μΐ 50 mM phosphate buffer pH 7.4 for 16 h at 4 °C. The wells were washed twice using wash buffer from Kaivogen Oy (Turku, Finland). Final blocking of the well surface was carried out with 200 μΐ 0.1 % BSA in the phophate buffer for 2 hours at 25 °C. The same 6404 antibody was conjugated with <i-biotin NHS ester (Sigma-Aldrich, St. Louis, USA) using 20-fold excess in 50 mM phosphate buffer pH 7.8. After conjugation the antibody was purified with NAP-5 column (GE Healthcare, Uppsala, Sweden) using TBS- buffer (50 mM Tris-Cl pH 7.5, 150 mM NaCl). Three replicates of 0 - 10 mg/L hCRP were incubated for 60 min in 50 μΐ of TBS-buffer in prewashed 6404 coated wells. The wells were washed once, and 50 ng of biotinylated 6404 antibody was added to the wells in 50 μΐ of TBS and incubated for 60 min. The wells were washed once and 50 ng streptavidin (BioSpa, Milan, Italy) in 50 μΐ of TBS was added, incubated for 10 minutes and washed once. Thereafter, 50 μΐ of 40 nM biotinylated europium chelates were added and incubated for 10 minutes. The wells were washed twice and measured with a Victor2 1420 multilabel counter (PerkinElmer, Wallac OY, Turku, Finland) in time -resolved luminescence mode using an excitation wavelength of 340 nm and an emission wavelength of 615 nm, a 400 μβ delay, and 400 μβ integration times. Spectroscopic properties of the chelates. The spectroscopic properties of the complexes were measured in 0.01 M TRIS/HCl buffer at pH 7.4 on the glycine functionalized complexes (lb, 6b, 7b), and the most important parameters are gathered in Table 1.
Table 1. Spectroscopic data for the Eu complexes in 0.01 M TRIS/HCl buffer at pH 7.4
The UV-Vis absorption spectra of the three Eu complexes are very similar, displaying a strong absorption band centred at ca 318 nm, corresponding to π→π¾ transitions on the pyridyl rings (see Figure 2 for lb). The presence of the /?ara-(thiourea)-toluyl substitution resulted in a strong bathochromic shift of this absorption band, when compared to non substituted pyridines for which the maximum of absorption can be found at 265-267 nm. Upon excitation into the π→π* absorption bands, all complexes display well resolved emission bands between 575 and 730 nm associated to f-f transitions on the europium atom. These emission bands correspond to the 5D0→7Fj transitions with J = 0 (single band at 575 nm), J= 1 (between 578 and 600 nm), J = 2 (strong, 605 to 625 nm), J = 3 (weak around 650 nm) and J = 4 (690 to 715 nm). The corresponding excitation spectra are perfectly superimposable with the absorption spectra, evidencing an efficient ligand to metal energy transfer process that is a good antenna effect. The luminescence decay profiles measured at the maximum of emission were all perfectly fitted with mono -exponential functions, pointing to the presence of single species in solution. The complex obtained from the heptadentate ligand of lb displayed the shorter lifetime (0.39 ms), the coordination sphere of the europium being probably unsaturated. This was confirmed by the calculation of the hydration numbers of the complexes according to the method developed by Horrocks using Beeby's coefficients (Table 1). While the heptadentate ligand of lb releases the place for two inner sphere water molecules, the replacement of one or two acetate functions by iminodiacetate ones resulted in the fulfilment of the coordination sphere and the removal of solvent molecules from the first coordination sphere. The Eu centred emission spectra of the complexes are presented in Figure 3. The 5D0→7F2 transition represents the most intense emission band. The main variations in the series are observed on this transition and on the pattern of the transition, this transition becoming more intense (compared those with J = 0 to 3) for 7b. Based on the emission spectra of the three complexes (Figure 2), it was possible to determine the europium centred quantum yield, ΦΕ0 from which one can calculate the sensitization efficiency, ^eff, that reflects the capacity of the ligand to transfer the absorb energy to the europium, using equation Where Φον is the overall luminescence quantum yield measured by direct method (Table 1).
The calculated values of ηβ and 0EU evidenced that the sensitization is almost the same for all compounds ranging from 41 to 54 %, as expected for a similar antenna unit. In contrast, the metal centred quantum yield of lb is largely affected by the presence of the two inner sphere water molecules, losing two third of the value obtained when the coordination sphere is saturated.
Determination of the conditional stability constants. The determination of the conditional stability constants of the different complexes was addressed by means of competition experiments with EDTA and DOTA. Only in the case of lb it was possible to displace the equilibrium in the presence of EDTA. Considering a conditional stability constant of 14.53 Log units for EDTA at this pH, the fitting resulted in a conditional stability constant of 16.7Log units for lb at pH = 7.4. For both 6b and 7b, even in the presence of large excess of EDTA, it was not possible to displace the equilibrium, and to extract the Eu atom from its coordinating ligand. Even DOTA which is known to form very stable complexes with Ln cations was not able to demetallate the chelates of the present technology even after three days at 80°C.
Conjugation to Bioactive Molecules and hCRP immunoassay. The applicability of the chelates was demonstrated in a sandwich-type hCRP immunoassay. Therefore, the chelates lb, 6b and 7b were conjugated with N-Biotinyl-3-aminopropylamine. The synthesized chelates 6c and 7c performed equally well in the hCRP assay. The biotin-chelate lc resulted in lower luminescence signal than the 6c and 7c which is in accordance with the measured quantum yields and emission lifetimes. The analytical detection limits for lc, 6c and 7c were 6.5, 1.5 and 1.9 respectively as calculated from 3 SD above the mean of the zero hCRP concentration and from the equations lc: y = 32515x - 34, R2 = 0,96; 6c: y = 87730x +16, R2 = 0,99; 7c: y = 90760x - 31, R2 = 0,99.
It will be apparent for an expert skilled in the field that other embodiments exist and do not depart from the spirit of the invention. Thus, the described embodiments are illustrative and should not be construed as restrictive.

Claims

1. A chelate comprising a lanthanide(III) ion selected from europium, terbium, samarium dysprosium and a chelating ligand of formula (I)
(I)
wherein
X is an aromatic unit, L is a linker formed from one to ten moieties, each moiety being selected from the group consisting of phenylene, alkylene containing 1-12 carbon atoms, ethynydiyl (-C≡C-), ethylenediyl (-C=C-), ether (-0-), thioether (-S-), amide (-CO-NH-, -CO-NR'-, -NH-CO- and -NR'-CO-), carbonyl (-CO-), ester (-COO- and -OOC-), disulfide (-SS-), sulfonamide (-S02- NH-, -S02-NR'-), sulfone (-S02-), phosphate (-0-P02-0-), diaza (-N=N-), and tertiary amine, wherein R' represents an alkyl group containing less than 5 carbon atoms, and L replacing a hydrogen anywhere in the parent compound, or not present,
A is a reactive group selected from isothiocyanate, bromoacetamido, iodoacetamido, maleimido, 4,6-dichloro-l,3,5-triazin-2-ylamino, pyridyldithio, thioester, aminooxy, azide, hydrazide, amino, alkyne, a methacroyl group, carboxylic acid, acid halide, and an active ester, wherein A' is cleaving group selected from CI, (CH3)2SO, H20, and N03 wherein - is the position of the linker L and wherein - is the position of linker L, and A replacing a hydrogen of the aromatic unit X when the linker L is not present, and
Ra is selected from -CH2COO and -(CH2)nN(CH2COCr)2, wherein n is 2 or 3, and Rb is-(CH2)mN(CH2COO")2, wherein m is 2 or 3 , and
Rc is selected from CH2COO , and -(CH2)iN(CH2COO")2, wherein 1 is 2 or 3.
2. The chelate according to claim 1 wherein the aromatic unit is selected from phenylethynyl, furyl, thienyl, phenyl, and pyrrole, and their substituted derivatives and wherein said substituents are selected from alkyl groups and alkoxy groups.
3. The chelate according to claim 1 wherein Ra is selected from -CH2COO" and
-CH2CH2N(CH2COO~)2, Rb is -CH2COO , and Rc is -(CH2)2N(CH2COO")2.
4. The chelate according to claim 1 wherein the chelating ligand has the formula (III)
wherein the reactive group A is selected from amino, iodoacetamido, isothiocyanato and 4,6- dichloro-l,3,5-triazin-2-ylamino, and the lanthanide is selected from europium and samarium.
5. The chelate according to claim 3 or 4 wherein the lanthanide is europium.
6. The chelate according to claim 1 wherein the aromatic unit is alkoxyphenyl group and the lanthanide is selected from terbium and dysprosium.
7. The chelate according to any of claims 1-6 wherein Ra is -CH2COO~.
8. A chelating agent of formula II
wherein X is an aromatic unit,
L is a linker formed from one to ten moieties, each moiety being selected from the group consisting of phenylene, alkylene containing 1-12 carbon atoms, ethynydiyl (-C≡C-), ethylenediyl (-C=C-), ether (-0-), thioether (-S-), amide (-CO-NH-, -CO-NR'-, -NH-CO- and -NR'-CO-), carbonyl (-CO-), ester (-COO- and -OOC-), disulfide (-SS-), sulfonamide (-S02- NH-, -S02-NR'-), sulfone (-S02-), phosphate (-0-P02-0-), diaza (-N=N-), and tertiary amine, wherein R' represents an alkyl group containing less than 5 carbon atoms, and L replacing a hydrogen anywhere in the parent compound2,
A is a reactive group selected from the group consisting of carboxylic acid or its salt, acid halide, carboxylic acid ester, an amino acid residue -CH(NHR1)R2 where R1 is a transient protecting group and R2 is a carboxylic acid or its salt, carboxylic acid halide or an active ester and a group of
-Z1-0-PZ2-0-R3 wherein one or two of the oxygen atoms optionally is replaced by sulfur,
Z2 is chloro or NR4R5,
R3 is a protecting group, R4 and R5 are alkyl groups including 1-8 carbons,
Z1 is absent or is a radical of a purine base or a pyrimidine base wherein the base is connected to the oxygen atom via either a) a hydrocarbon chain, which is substituted with a protected hydroxymethyl group, or b) a furan ring or pyrane ring,
Rd is selected from -CH2COOR" and -(CH2)„N(CH2COOR")2, wherein n is 2 or 3,
Rb is -(CH2)mN(CH2COOR")2, wherein m is 2 or 3, and
Rc is selected from CH2COOR", and -(CH2)!N(CH2COOR")2, wherein 1 is 2 or 3 and wherein R" is a protecting group.
9. The chelating agent according to claim 8 wherein Rd is selected from -CH2COOR" and -CH2CH2N(CH2COOR")2, Rb is -(CH2)2N(CH2COOR ")2, and Rc is -CH2COOR" .
10. A biomolecule conjugated with a chelate according to any of claims 1-7 wherein the biomolecule is selected from the group consisting of oligopeptide, oligonucleotide, DNA,
RNA, modified oligo- or polynucleotide, protein, oligosaccharide, polysaccharide, phospholipide, PNA, LNA, antibody, antigen steroid, biotin, hapten, drug, receptor bindig ligand, and lectine.
11. A biomolecule obtained by synthesis on a solid phase by introduction of a chelating agent according to claim 8 or 9 into the biomolecule structure followed by deprotection and introduction of a lanthanide ion.
12. The biomolecule according to claim 11 wherein said biomolecule is selected from an oligopeptide and an oligonucleotide.
13. A method of carrying out a specific bioaffinity assay using a biomolecule of any of claims 10-12 with an analyte to be determined.
14. Use of a biomolecule according to any of claims 10-12 in a specific bioaffinity binding assay utilizing fluorometric or time -resolved fluorometric determination of a specific luminescence.
15. The use according to claim 14 wherein the specific bioffinity assay is selected from a heterogenous immunoassay, a homogenous immunoassay, a DNA hydridization assay, a receptor binding assay, an immunological assay and an immunohistochemical assay.
EP13783074.1A 2012-09-24 2013-09-20 Chelates, chelating agents, conjugates derived thereof and their use Active EP2897967B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20120311 2012-09-24
PCT/FI2013/050912 WO2014044916A1 (en) 2012-09-24 2013-09-20 Chelates, chelating agents, conjugates derived thereof and their use

Publications (2)

Publication Number Publication Date
EP2897967A1 true EP2897967A1 (en) 2015-07-29
EP2897967B1 EP2897967B1 (en) 2017-06-21

Family

ID=49486500

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13783074.1A Active EP2897967B1 (en) 2012-09-24 2013-09-20 Chelates, chelating agents, conjugates derived thereof and their use

Country Status (4)

Country Link
US (1) US20150307774A1 (en)
EP (1) EP2897967B1 (en)
ES (1) ES2634146T3 (en)
WO (1) WO2014044916A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7523883B2 (en) * 2015-08-13 2024-07-29 ザ ジェネラル ホスピタル コーポレイション Manganese-based chelate conjugates for molecular MR imaging
FI128833B (en) 2019-12-09 2021-01-15 Abacus Diagnostica Oy Luminescent lanthanide(III) chelates
JP2023509452A (en) 2020-01-03 2023-03-08 バーグ エルエルシー Polycyclic Amides as UBE2K Modulators to Treat Cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761481A (en) 1985-03-18 1988-08-02 Baxter Travenol Laboratories, Inc. Substituted pyridine derivatives
SE8502573D0 (en) 1985-05-23 1985-05-23 Jouko Kanakre FLUORESCENT LANTHANIDE CHELATES USEFUL AS LABELS OF PHYSIOLOGICALLY ACTIVE MATERIALS
US5714327A (en) 1990-07-19 1998-02-03 Kreatech Diagnostics Platinum-containing compounds, methods for their preparation and applications thereof
US6080839A (en) 1998-06-25 2000-06-27 Wallac Oy Labeling reactants and their use
DE60141871D1 (en) 2000-05-05 2010-06-02 Wallac Oy Oligonucleotide labels and their use
US7282581B2 (en) 2001-11-02 2007-10-16 Wallac Oy Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof
US7018851B2 (en) 2003-02-13 2006-03-28 Innotrac Diagnostics Oy Biospecific binding reactants labeled with new luminescent lanthanide chelates and their use
CN1871233B (en) 2003-08-29 2011-07-13 沃拉克有限公司 Novel chelating agents and chelates and their use
EP1694672B1 (en) 2003-12-18 2012-06-20 Wallac Oy Novel chelating agents and highly luminescent and stable chelates and their use
JP5237949B2 (en) 2006-08-18 2013-07-17 アバクス ディアグノスティカ オイ Luminescent lanthanoid labeling reagent and use thereof
FI120538B (en) 2007-09-05 2009-11-30 Wallac Oy Chelates, chelating agents and conjugates derived therefrom
FI20080624A0 (en) * 2008-11-17 2008-11-17 Wallac Oy Chelates, chelating compounds and conjugates derived from them

Also Published As

Publication number Publication date
WO2014044916A1 (en) 2014-03-27
ES2634146T3 (en) 2017-09-26
EP2897967B1 (en) 2017-06-21
US20150307774A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
EP2753674B1 (en) Luminescent lanthanide chelates having three chromophores and their use
US9518186B2 (en) Luminescent lanthanide chelates with enhanced excitation properties
US20100036102A1 (en) Novel chelating agents and highly luminescent and stable chelates and their use
JP6310575B2 (en) A novel chromophore structure for lanthanide chelates
EP1658282B1 (en) Novel chelating agents and chelates and their use
US8221719B2 (en) Luminescent lanthanide (III) chelates, chelating agents and conjugates derived thereof
WO2010055207A1 (en) Chelating, chelating agents and conjugates deriver thereof
US9944657B2 (en) Luminescent lanthanide chelates having three chromophores an their use
EP0967205B1 (en) Labeling reactants and their use
EP2897967A1 (en) Chelates, chelating agents, conjugates derived thereof and their use
EP3212733B1 (en) New chromophoric structures for macrocyclic lanthanide chelates
US20080167443A1 (en) Novel chelating agents and highly luminescent and stable chelates and their use
WO2009115644A1 (en) Lanthanide(iii) chelates comprising beta-diketones and conjugates derived thereof
EP2794812B1 (en) Novel luminescent lanthanide chelates with enhanced excitation properties
JP2023505393A (en) Luminescent Lanthanide (III) Chelate

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150424

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160523

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 213/36 20060101ALI20170103BHEP

Ipc: G01N 33/58 20060101ALI20170103BHEP

Ipc: C07F 5/00 20060101AFI20170103BHEP

Ipc: C09K 11/06 20060101ALI20170103BHEP

Ipc: A61K 49/00 20060101ALI20170103BHEP

Ipc: C09K 11/07 20060101ALI20170103BHEP

Ipc: C12N 15/11 20060101ALI20170103BHEP

Ipc: G01N 33/533 20060101ALI20170103BHEP

INTG Intention to grant announced

Effective date: 20170203

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 902839

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170715

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013022615

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2634146

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20170926

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 5

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170921

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170922

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 902839

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170921

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171021

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013022615

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

26N No opposition filed

Effective date: 20180322

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20170930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170920

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170930

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170930

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170920

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170930

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170920

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20130920

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230920

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230928

Year of fee payment: 11

Ref country code: DE

Payment date: 20230920

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231124

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230927

Year of fee payment: 11